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Endothelin system members including endothelin-1, endothelin-2, endothelin-3, endothelin receptors, and endothelin converting 
enzyme are considered major regulating factors in cancer cell biology and cancer microenvironment. Endothelins are members 
of the matrix metalloproteinase superfamily of proteases, which are released from pre-proteins, bind to their receptors with 
differential affinity, and are degraded following cellular uptake. For their structural similarity, endothelin-2 and endothelin-3 
can be regarded as natural competitors for the endothelin-1 receptors and as natural antagonists of endothelin-1. Endothelin-1 is 
regulated at several levels, primarily at the level of transcription. Remarkably, endothelin-1 is overexpressed in colorectal cancer, 
and elevated plasma levels were found in colorectal cancer patients. Endothelin receptor type A has an unequal distribution in 
the colon, as it is over-expressed in the proximal and distal segments of the colon. Compared with normal mucosal tissue, there is 
high expression of endothelin receptor type A and low expression of endothelin receptor type B in colorectal cancer at all Dukes 
stages. By binding to endothelin receptor type A, endothelin-1 leads to down-regulation of epithelial and increased expression 
of mesenchymal markers. Also, endothelin-1 acts as anti-apoptotic factor through multiple pathways like PI3K-dependent AKT 
activation or NF-κB signaling. Members of the endothelin system might be used as cancer biomarker and from a therapeutic point 
of view, targeting the endothelin axis is a promising aim. In effect, potential drugs may include endothelin converting enzyme 
inhibitors as well as selective and non-selective antagonists of endothelin receptor types A and B. 
Biomed Rev 2014; 25:1-13
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INTRODUCTION
The endothelin (EDN) system has a very important role in 
a variety of physiological and pathophysiologic processes 
including development, tissue differentiation, vasomotor tone, 
hormone production (1), pulmonary disease, cardiovascular 
disorders, renal diseases, wound healing, neurotransmission, 
and cancer biology (2). There are quite a few reviews 
describing the role of the EDN system in cancer, but there 
is limited information regarding its role in colorectal cancer. 
Because of our own interest, which was sparked by the growing 
evidence that the EDN system has bearing on colorectal cancer 
development, growth and metastasis, we found it appropriate 
to fill in this gap and review the EDN system for its role in 
this type of cancer.
COMPONENTS OF THE ENDOTHELIN SYSTEM
The EDN system consists of endothelin-1 (EDN-1), endothelin-2 
(EDN-2), endo thelin-3 (EDN-3), the G-protein-coupled 
receptors, endothelin receptor type A (EDNRA) and endothelin 
receptor type B (EDNRB), and endothelin converting enzyme 
(ECE) (3). Endothelins are characterized by a single alpha-helix 
and two disulfide bridges. There are three known isoforms, 
EDN-1 (or ET-1), EDN-2 (or ET-2) and END-3 (or ET-3) (4). 
A scheme of the EDN isoforms is given in Figure 1.
Figure 1. Scheme of the secondary structure and the amino acid sequence of endothelin-1 (EDN-1), endothelin-2 (EDN-
2), and endothelin-3 (EDN-3). Amino acids are symbolized by circles. Sulfur double bonds between cysteine residues are 
indicated by a straight line. Differences in the amino acid composition of EDN-2 and EDN-3 versus EDN-1 are indicated by 
blue circles and red amino acid abbreviations. The numbers below the circles denote the amino acid sequence from the amino 
to the carboxyl terminus (The sequences correspond to the following datasets: EDN-1: UniProtKB/Swiss-Prot: P05305.1; 
EDN-2: GenBank: EAX07175.1; EDN-3: NP_996917.1) 
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Endothelin-1
Endothelin-1 is a member of the matrix metalloproteinase 
superfamily of proteases (5). The primary transcript of EDN-
1 is termed prepro-EDN-1, the gene of which is located on 
chromosome 6, there spanning 6.8 kb and containing five exons 
(6). This protein is then transformed to big-EDN-1, and further 
to the active 21-aa EDN-1 via endothelin converting enzyme 
(ECE). A corresponding scheme is shown in Figure 2. 
 Endothelin-1 is synthesized, expressed and secreted not 
only from endothelial cells but also from macrophages, 
fibroblasts, vascular endothelial cells, smooth muscle cells, 
neurons, and epithelial cells of the airways and oral cavity 
(7). Degradation of EDN-1 is done by EDN-1 receptor 
type B (EDNRB) mediated cellular uptake followed by 
lysosomal degradation (8), or through degradation by the 
extracellular neutral endopeptidase 24.11 (9). Endothelin-1 
is well known as a potent vasoconstrictor (10) and has 
a role in tumor initiation and progression via autocrine 
and paracrine mechanisms (6). It acts through different 
signaling pathways and is involved in normal cell functions 
as well as in those contributing to cancer development and 
progression, including cell proliferation, apoptosis, epithelial 
mesenchymal transition, invasion, metastasis, and tumor 
angiogenesis. Based on these properties, EDN-1 and its 
signaling axis are considered very attractive targets for cancer 
therapy (11).
Figure 2. Scheme of endothelin-1 synthesis: The endothelin gene is located on chromosome 6 and comprises five exons (blue 
boxes) and six introns. Following transcription, the 216 amino acids containing prepro-endothelin-1 is expressed, which then 
is cleaved by furin proteases to become big endothelin (big-EDN-1) and finally by endothelin converting enzymes (ECE-1 and 
ECE-2) to become active endothelin 1 (EDN-1).
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Endothelin-2 and endothelin-3
There is less research published on the roles of EDN-2 and 
EDN-3 in cancer as com pared to EDN-1. The EDN-2 gene is 
present on chromosome 1, while the EDN-3 gene is located 
on chromosome 20 (12). In comparison to EDN-1, which is 
distributed in all rat organs examined (13), EDN-2 expression 
is more restricted to certain human and rat organs, including 
the intestines (14). Interestingly, EDN-2 has an unequal 
distribution in the colon; it is immunolocalized at the middle 
and upper parts of a crypt in the proximal colon and in the 
base of crypts in the distal colon (15). Endothelin-2 is known 
as a hypoxia inducible and antihypoxic factor. In human breast 
cancer, EDN-2 is reported to be a survival factor against 
hypoxia, whereas in a rat model of colonic tumorigenesis, 
EDN-2 and EDN-3 expression is lost several weeks before 
the onset of colon cancer. However, if these rats were treated 
with 5-aza-2′-deoxycytidine (5-aza-dC), their colonic mucosa 
showed re-expression of both, EDN-2 and EDN-3, but with 
a preference for EDN-2, the expression of which was greater 
than that of EDN-3. Moreover, forced re-expression of 
EDN-2 and EDN-3 in human colon cancer cells in vitro led 
to inhibition of invasion and migration. Thus, in human and 
rat colon cancer cell lines as well as in human primary colon 
cancers, there is down-regulation and hyper-methylation of 
the EDN-2 and EDN-3 genes. For their structural similarity, 
EDN-2 and EDN-3 can be considered as natural competitors 
for the EDN-1 receptor and as natural antagonists of EDN-1, 
and in line with this notion they have anticancer effects (3). 
A short summary is shown in Table 1 regarding the increased 
expression of members of the EDN system in colon cancer 
cell lines SW480, SW620 and HT29 following exposure to 
the demethylating agent 5-aza-2′-deoxycytidine (unpublished 
own results). 
Endothelin receptors type A and B
Endothelin receptors type A and B (EDNRA and EDNRB) 
are members of the family A of G protein-coupled receptors 
(GPCRs, the ‘druggable’ class). EDNRA affinity to EDN-
1 and EDN-2 is twofold higher than its affinity to EDN-3, 
while the affinity of EDNRB is equal to EDN-1, EDN-2 and 
EDN-3 (6). The genes of EDNRA and EDNRB are located 
on chromosomes 4 and 13 (16). There is a heterogeneous 
distribution of the endothelin receptors at cellular, tissue and 
organ levels. EDNRA and EDNRB may have the same or the 
opposite effect, but in general most of the EDN-1 effect is 
mediated by EDNRA (7). EDNRA has an unequal distribution 
in the colon, as it is over-expressed in the proximal and distal 
segments of the colon (17). Endothelin receptors type B is 
considered as the predominant receptor in normal colon, 
but in colon cancer it is down-regulated in cancer associated 
blood vessels, fibroblasts and epithelial cells (17). Moreover, 
epigenetic alteration of EDNRB expression by aberrant 
methylation has an important role in the pathogenesis of 
hepatocellular carcinoma (18), and in gastric cancer (19). 
 Activation of EDNRB by EDN-1 in normal and some tumor 
cells leads to the induction of EDN-1 clearance, which then 
stimulates cellular apoptosis, thus having an anticancer effect 
(20). However in other tumor types EDNRB enhances cancer 
progression and was found to be overexpressed, such as in 
melanoma (21) and oligodendroglioma (22). In line with this, 
BQ788, a specific EDNRB antagonist, can inhibit the growth 
of human melanoma tumors cells in nude mice (21).
 There are three types of EDNRA and EDNRB expression 
in cancer in general: the first type expresses predominantly 
EDNRA, as found for colon, pancreatic, gastric, renal and 
breast, nasopharyngeal, thyroid, and prostate cancers; the 
second type expresses predominantly EDNRB, as in melanoma 
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and brain tumors (glioblastoma and astrocytoma); the third 
type expresses both, EDNRA and EDNRB, as in oral, lung, 
bladder, vulvar and ovarian cancers (23).
Endothelin converting enzyme
Endothelin converting enzyme (ECE) is a membrane bound 
enzyme, which is responsi ble for EDN-1 production and can 
control the level of EDN-1. There are two types of endothelin 
converting enzyme, ECE-1 (24) and ECE-2 (25). Both of 
them are membrane-bound, zinc-binding metalloproteases. 
Endothelin converting enzyme-1 is present mainly at the cell 
surface, while ECE-2 exists predominantly in the cytosol. Also, 
ECE-1 has a wide tissue distribution with highest expression 
in liver, while ECE-2 has a neuroendocrine distribution. Both 
of them can act on big-EDN-1, big-EDN-2 and big-EDN-3, 
but with higher affinity to big EDN-1 (7).
 The ECE-1 gene is located on chromosome 1 and has the 
four isoforms ECE-1a, ECE-1b, ECE-1c and ECE-1d (26). 
These isoforms have different subcellular localization and 
effects due to differences in their N-terminal cytoplasmic 
regions (27).
VARIATION OF ENDOTHELIN AXIS COMPONENTS’ 
EXPRESSION IN COLORECTAL CANCER 
Endothelin-1 is overexpressed in many gastrointestinal 
tumors including colorectal and gas tric cancers (28). 
Increased expression of EDN-1 was demonstrated by 
immunohistochemistry and immune-electron-microscopy 
in colorectal cancer primaries and liver metastases, as well 
as in endothelial and stromal cells (29, 30). Over-expression 
of prepro-EDN-1, ECE-1, and EDNRA and EDNRB was 
found in human colon adenomas and adenocarcinomas as 
compared to normal colon. Also, prepro-EDN-1 and ECE-1 
were overproduced from carcinoma and stromal vessel cells, 
thus they may be considered as the source of local EDN-1. 
There are large amounts of EDNRA in stromal myofibroblasts 
of cancer tissue, and large amounts of EDNRB in endothelial 
cells and myofibroblasts (2, 31).
 Elevated plasma levels of EDN-1 were found in colorectal 
cancer patients with or without liver metastasis (32). EDN-1 
is over-expressed in endothelial cells within liver metastasis in 
comparison to surrounding vessels in patients with colorectal 
cancer, thus EDN-1 can modulate metastatic liver blood 
vessels (30). In fact, in 80% of primary human colon cancers 
there is EDN-1 overexpression (33). In normal mucosa and 
early stage colon cancer cells there is still normal expression 
of EDN-1, but overexpression develops during later stages of 
colon cancer (15). The role of EDN-1 in cancer may be due to 
over-expression of EDN-1 or overexpression of its receptors, 
or their signaling pathways. These changes in EDN-1 axis are 
due to genetic and epigenetic changes as DNA methylation 
and histone modification (6). Similarly, in human and rat colon 
cancers there are very low to undetectable expression levels 
of EDN-2 and EDN-3, as a result of epigenetic silencing (3).
 Compared with normal mucosal tissue, there is high 
expression of EDNRA and low expression of EDNRB in 
colorectal cancer (17, 34) at all Dukes stages (35). This was 
found also in colorectal cancer cells and cancer associated cells 
(fibroblasts and endothelial cells) in comparison with normal 
tissue (17). In line with these findings in colorectal cancer, 
there is similar expression in other gastrointestinal cancers 
such as gastric cancer (19, 36) and hepatocellular cancer 
(18). Regarding the colorectal cancer cell lines LIM1215, 
HT29, SKCO1, SKCO17 and LoVo, there is high expression 
of EDNRA and low expression of EDNRB in comparison to 
normal colon (35).
REGULATORY FACTORS OF ENDOTHELIN-1 
The secretion of EDN-1 is stimulated by mechanical factors 
(vascular shear stress), meta bolic factors (hypoxia), endocrine 
factors (thrombin, insulin, aldosterone, adrenaline, leptin and 
cortisol) and paracrine factors (transforming growth factor 
beta, angiotensin II and inflammatory mediators) (7). Also, 
EDN-1 production can be inhibited by nitric oxide, prostacyclin 
and atrial natriuretic peptide (1). Endothelin-1 is regulated at 
several levels, primarily at the level of transcription by more 
than 20 different stimuli, with each acting on specific tissues 
and cells and having its own regulatory factors. Endothelin-1 
is controlled by a TATA box-containing promoter. Activator 
protein-1 (AP-1) is present within the proximal promoter and 
contains binding sites for FOS and JUN transcription factors. 
Also, there are binding sites for transforming growth factor-β 
(TGF-β)-activated SMAD transcription factors, GATA family 
transcription factors and hypoxia-inducible factor 1 (HIF1) in 
the proximal EDN-1 promoter (see Fig. 3). 
 Meanwhile, there are other binding sites in the distal EDN-
1 promoter such as a hormone-responsive element, a nuclear 
factor-κB (NF-κB), an E-box motif and two nuclear factors 
of activated T cell binding sites. EDN-1 is regulated also at 
the post transcriptional level, as the 3ʹ-untranslated region 
(3ʹ UTR) of EDN-1 contains AUUUA motifs, which bind to 
certain proteins and regulate RNA degradation or stabilization. 
Also, EDN-1 mRNA can be regulated by microRNA species 
(miR-155 or miR-199) (37). 
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ENDOTHELIN-1 ROLE IN CANCER CELL BIOLOGY
Endothelin-1 activates several intracellular pathways including 
phospholipases C and D, phos pholipase A2, adenylate cyclase 
and guanylate cyclase. The former two enzymes stimulate 
protein kinase C (PKC) and phosphoinositide 3-kinase (PI3K), 
and this leads to stimulation of the mitogen activating protein 
kinase (MAPK) pathway (28). In colorectal cancer patients 
there is up-regulation of EDNRA and down-regulation of 
EDNRB, which has bearing on the AKT pathway. This 
pathway is characterized by up-regulation of AKT, hypoxia-
inducible factor 1-alpha subunit (HIF1α) and VEGF that lead to 
stimulation of angiogenesis and improved cell survival. Also, 
there is an increase in the expression of glycogen synthase 
kinase 3 beta (GSK3B), snai1 homologue 1(SNAI1), catenin 
(cadherin-associated protein) beta 1 (CTNNB1, β-catenin), and 
cyclin D1. Moreover, there is over-expression of transcription 
factors, which are responsible for mesenchymal cell 
phenotypes like goosecoidhomeobox (GSC), twist homologue 
1 (TWIST), lymphoid enhancer-binding factor 1 (LEF1), E2A 
immunoglobulin enhancer binding factors E12/E47 (TCF3), 
forkhead box C1 (FOXC1) and FOXC2. Over-expression 
of SNAI1, TCF3, TWIST, FOXC1, FOXC2 and GSC lead 
to down-regulation of E-cadherin, and this down-regulation 
in primary colon cancer was described to be associated with 
lymph node and liver metastasis (38). However, others reported 
no difference in E-cadherin expression in colon carcinomas 
(39).
 In human colon cancer, inactivating mutations of the 
APC gene or activating mutations of the β-catenin gene 
lead to β-catenin/TCF4 complex formation on the EDN-1 
promotor, and this complex finally stimulates transcription 
of EDN-1 and subsequent over-expression (32). There is a 
positive feedback loop between EDN-1 and β-catenin via 
the PI3K pathway (40). In normal cells, free β-catenin is 
degraded after phosphorylation by the APC/Axin/GSK3b 
complex (41). In 85% of sporadic colon cancer patients, 
there is mutational inactivation of the APC gene, which leads 
to aberrant β-catenin pathway activation (42). In a minority 
of sporadic colon cancers cases, there is a mutation in the 
residues of the β-catenin gene, which leads also to β-catenin 
pathway activation because β-catenin cannot be targeted for 
proteasomal degradation (43). As a result, Wnt signaling 
stabilizes free cytoplasmic β-catenin, then stable β-catenin can 
enter into the nucleus and form a complex with the lymphoid 
enhancer factor/T-cell factor (LEF/TCF) family of DNA 
binding proteins, and start its tumorigenic gene transcription 
(44).
Cell proliferation 
Endothelin-1 acts as autocrine promoter of cell proliferation 
via EDNRA (45). In addition, mitogenic effects of EDN-1 
in cell proliferation can be promoted by the action of other 
growth factors like EGF, basic fibroblast growth factor, 
insulin, insulin-like growth factors 1 and 2, platelet-derived 
growth factor, TGFβ and IL-6 (6). As established for colon 
cancer cells, activation of EGFR occurs through the G protein 
coupled receptors (GPCR), their β-arrestin regulators and the 
c-Src pathway (46).
Cell survival
Endothelin-1 acts as anti-apoptotic factor through multiple 
pathways like PI3K-dependent AKT activation or NF-κB 
signaling (47). Likewise, it acts as anti-apoptotic and survival 
factor against FAS Ligand (FASL)-induced apoptosis in colon 
Figure 3. Scheme of endothelin-1 promotor regulation: Core motives (GATA; GATA transcription factors), HIF-1 (hypoxia 
inducible factor-1); AP-1 (activator protein-1); CAAT (consensus sequence signaling the RNA transcription factor binding 
site); FOXO (forkhead box); Vezf1 (vascular endothelial zinc finger binding protein f1); TATA [consensus sequence signaling 
the binding site of either general transcription factors or histones) are indicated by circles. Nucleotide positions are numbered 
relative to the primary transcriptional start site and correspond to the human EDN1 gene (NCBI accession no. NC_000006). 
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carcinoma (48). MYC is one of the genes, which is targeted by 
the β-catenin pathway. EDN-1 is responsible for suppression 
of MYC-induced and FasL-induced apoptosis. Also, EDN-
1 acts as a survival factor against apoptosis of colon cancer 
cells as a result of its inhibiting the β-catenin pathway, and 
this may be due to AKT activation (49). Endothelin-1 receptor 
antagonists promote the effect of conventional chemotherapy 
in many cancer cell lines including colon cancer by induction 
of cancer cell apoptosis (50).
Migration and invasion
Cancer cells secrete proteases in order to lose polarity and 
cell to cell junctions, and ac quire mesenchymal character 
to invade the extracellular matrix (ECM) and subsequently 
form metastases (51). Endothelin-1 modulates the gene 
transcription, secretion and activation of the resultant pro-
enzymes of two families of metastasis related proteinases, the 
urokinase-type plasminogen activator (uPA) system and the 
matrix metalloproteinases (MMP). Also, EDN-1 contributes 
to activation of p125 focal adhesion kinase (FAK), paxillin 
and RHO, which are involved in tumor cell motility and 
invasion (6). Epithelial to mesenchymal transition (EMT) 
is part of the initial stage of any metastatic process within 
cancer progression, in which cancer cells will lose many of 
their epithelial characters, like cell to cell adhesion, polarity 
and lack of motility, and transfer to become more like 
mesenchymal cells (38). By binding to EDNRA, EDN-1 leads 
to down-regulation of epithelial markers as E-cadherin and 
increased expression of mesenchymal markers as β-catenin, 
Snail, N-cadherin and vimentin (52).
 The phosphatase and tensin homolog (PTEN) is considered a 
tumor suppressor gene, which inhibits the PI3K/AKT pathway 
as well as the EDN axis (53). In human colon cancer cells, loss 
of PTEN can induce EMT (54). It is found significantly down-
regulated in patients with colorectal cancer metastasis, especially 
in comparison with non-metastatic disease (38).
Metastasis
Metastasis is a complex process that needs interaction between 
cancer cells with the host microenvironment, and it involves 
tumor cell invasion, epithelial mesenchymal transition (EMT), 
shedding from the primary tumor, intravasation, arrest within 
blood vessels, extravasation and colonization of a preferential 
organ. EDN-1 starts autocrine and paracrine signaling cascades 
in tumor, immune and stromal cells, at both primary and distant 
sites, that lead to cancer invasion and metastasis (32).
ENDOTHELIN-1 AND CANCER STROMA
Endothelin-1 has an enhancing effect on cancer cell 
proliferation, survival, invasion and migra tion; also it has an 
effect on cancer stroma cells such as fibroblasts (proliferation, 
migration, contraction, ECM remodeling), macrophages 
(chemo-attraction, ECM remodeling) and endothelial cells 
(proliferation, angiogenesis) (5). Endothelin-1, which is 
produced by stromal and tumor cells, acts through different 
signaling pathways by EDNRA activation (AKT, MAPK, 
PKC, EGFR), and leads to stimulation of angiogenesis (by 
HIF-1a, VEGF, Cox-1/-2, PGE2), anti-apoptotic effects 
(AKT, NFKB), cell migration and adhesion (integrins, ILK, 
FAK, cadherins / catenins, connexins), increased invasion and 
expression of MMP and uPA (55). Endothelin-1 can stimulate 
fibroblast growth more by interacting with EDNRA, migration 
more by EDNRB, and fibroblast contraction by both of them. 
Also, it can stimulate the secretion of tissue inhibitor of MMP-
1 (TIMP-1), matrix metalloproteinase 2 (MMP-2), connective 
tissue growth factor (CTGF), and collagen XI, but has no 
effect on matrix metalloproteinase 3 (MMP-3). The increases 
in TIMP-1 and MMP-2 can be blocked by an EDNRA blocker 
more than an EDNRB blocker (56). Fibroblast cells isolated 
from normal tissue adjacent to colon cancer expressed EDNRA 
and EDNRB (28). In vitro, EDN-1 can stimulate growth, 
migration, contraction and the production of ECM-modifying 
proteins of fibroblasts, which were isolated from normal tissues 
adjacent to colon cancers (56). Thus, EDN-1 stimulates a 
stroma, which is supportive for tumor growth and progression, 
through its effect on tumor cells, macrophages and fibroblasts 
(6). Endothelin-1 stimulates endothelial cell migration and 
proliferation by EDNRB (57). Endothelin-1 receptor type B is 
over-expressed in endothelial cells and myofibroblasts of and 
around colorectal cancer vessels in comparison with normal 
colon mucosa. The EDN system affects tumor vasculature 
through interaction between myofibroblasts with endothelial 
cells and EDNRB induction (31).
ENDOTHELIN-1 AND STEM CELLS
There is interaction between cancer cells and mesenchymal 
stem cells (MSC) in co lon cancer. Following subcutaneous 
injection of human colorectal cancer cells and MSC into 
immune-deficient mice, it was found that MSC can increase 
the growth rate of tumor cells and their related angiogenesis 
in comparison to the effect of carcinoma-associated fibroblasts 
or normal colonic fibroblasts. Also, MSC stimulate secretion 
of EDN-1 from cancer cells via interleukin-6 (IL-6), which 
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in turn acts through Akt and ERK pathways of endothelial 
cells to stimulate recruitment of endothelial cells and tumor 
angiogenesis. This pathway can be blocked in MSC by siRNA, 
or in cancer cells through EDN-1 inhibition or knockdown, or 
in endothelial cells through inhibition of ERK and Akt (58).
 The CD133 antigen is used as marker for cancer stem cells 
in colon cancer. These CD133 positive cancer stem cells show 
over-expression of EDN-1 and nuclear receptor subfamily 4, 
group A, member 2 (NR4A2) transcripts, and there is a relation 
between the expression of CD133, EDN-1 and NR4A2, as 
shown by siRNA knockdown of CD133 expression in CaCo-2 
colorectal cancer cells, which caused a significant reduction 
in the expression of EDN-1 and NR4A2 (59).
ENDOTHELIN SYSTEM MEMBERS AS BIOMARKERS IN 
CANCER
In patients with colorectal cancer, there are high plasma levels 
of Big-EDN-1, and these levels are significantly higher in 
patients with liver metastasis, thus suggesting that Big-EDN-1 
plasma levels can be used as a marker of colorectal cancer 
presence and disease progression (29). Preoperative plasma 
levels of big-EDN-1 can be used as a prognostic marker for 
overall survival in patients with colorectal cancer , and can be 
used as a parameter among others for adjuvant therapy (32). In 
contrast, other publications indicate that plasma levels of big-
EDN-1 have no prognostic value in primary colorectal cancer 
patients (60). In line with this, elevated levels of serum EDN-1 
had no prognostic value in colorectal cancer patients (61). Also, 
in colorectal cancer patients increased EDNRA was associated 
with increased tumor grade and reduced patient survival (34). 
There was loss of EDN-2 and EDN-3 in rat colon mucosa 
several weeks before the onset of colon cancer, favoring the 
notion that they can be used as early biomarker of cancer 
colon (3). Moreover, EDN system members help as prognostic 
factors in other cancers. EDN-1 expression in bladder cancer 
tissue is considered as a highly prognostic factor for patient 
survival, while plasma levels of big-EDN-1 can be an early 
diagnostic factor in patients with invasive breast cancer (62).
Endothelin receptor antagonists in colorectal cancer
From a clinical point of view, targeting the EDN axis is a 
promising aim in cancer therapy; which includes endothelin 
converting enzyme inhibitors as well as selective and non-
selective antagonists of EDNRA and EDNRB. A selection of 
some of these agents is shown in Table 2. 
 Endothelin-1 receptor antagonists have a promising future 
in cancer therapy, especially with the invention of two oral 
EDNRA antagonists (ABT-627; atrasentan and ZD4054; 
zibotentan) (5). EDNRA antagonists are used in clinical 
trials of many types of cancer. For example, there is growing 
interest in using EDN receptor antagonists for prostatic cancer 
therapy (63). So far, however, there are only few trials in 
colorectal cancer patients. EDNRA selective antagonists (such 
as atrasentan and zibotentan) or dual EDNRA and EDNRB 
antagonists (such as macitentan) have inhibited colon cancer 
growth and induced apoptosis in vivo and in vitro, especially 
when combined with conventional chemotherapy (6). The 
human colorectal cancer cell lines LIM1215 and HT29 express 
Table 2. Selected antagonists of the endothelin system 
Antagonist Type Company
Atrasentan (ABT-627/A-147627) EDNRA antagonist Abott 
Darusentan (LU-135252) EDNRA antagonist Abott 
Zibotentan or ZD4054 EDNRA antagonist Astra Zeneca
BQ-788 EDNRB antagonist Bachem 
BQ123 EDNRA antagonist Bachem 
Ambrisentan (LU208075/BSF-208075) EDNRA antagonist Myogen 
Bosentan (RO 47-0203) EDNRA & EDNRB antagonist Actelion
Phosphoramidon Endothelin converting enzyme inhibitor Cayman Chemicals
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EDN-1, EDNRA and EDNRB. Addition of exogenous EDN-1 
increased their cell number in a dose dependent manner, and 
these increases in cell number were inhibited by EDNRA 
antagonists BQ123 and BQ610, but not the EDNRB antagonist 
BQ788 (64). Specifically, the EDNRA antagonist BQ123 
inhibited colorectal cancer cell proliferation in vitro. This 
was due to the fact that EDN-1 increased the proliferation 
of colorectal cancer cell lines (HT29, LIM1215 and SW620) 
by stimulation of DNA replication via EDNRA, and the 
effect was mediated via pertussis toxin-sensitive G proteins, 
phosphoinositide 3-kinase (PI3K), protein kinase C (PKC) and 
transactivation of the epidermal growth factor (EGF) receptor 
(65).
 In colorectal cancer cell lines and associated fibroblasts 
isolated from patient tissues, cellular proliferation is inhibited 
by the EDNRA antagonist zibotentan; but migration is 
inhibited by the EDNRB antagonist BQ788 more than by 
the EDNRA antagonist, while contraction is inhibited by the 
combined use of EDNRA and EDNRB antagonists. Recently, 
zibotentan has been recommended for use as adjuvant therapy 
in colorectal cancer patients (28).
In line with this, the dual EDNRA and EDNRB antagonist 
bosentan incompletely inhibited tumor progression in an 
experimental rat model of colon carcinoma induction; it led 
to less densely packed tumor cells with less collagen matrix 
around tumor nodules (31). 
 In a rodent model of colorectal cancer, intraportal injection 
of BQ123, the EDNRA antagonist, inhibited micro-metastasis 
of cancer, especially if injected at the time when cancer cells 
were injected and not after that, because BQ123 can inhibit 
the effect of EDN1/EDNRA during cancer cell implantation 
and micro-metastasis formation (33).
 Endothelin-1 inhibits FASL induced apoptosis in colorectal 
cancer, but bosentan, a dual EDNRA and EDNRB receptor 
antagonist, increases FASL induced apoptosis in human (HT-
29 and SW480) and rat (PROb and REGb) colon cancer cell 
lines. This inhibition is mediated by protein kinase C (PKC). 
Thus, EDN-1 acts as an anti-apoptotic factor not just as a 
direct proliferative agent. Bosentan usage in peritoneal tumors 
derived from a syngeneic rat colonic adenocarcinoma cell 
line led to a decreased death rate and a lower tumor grade in 
comparison with untreated rats, but it did not control tumor 
progression (48, 50, 66).
 In SW480 colorectal cancer cells, over-expression of 
EDNRA by an EDNRA expression vector led to increased 
cell invasion, cell survival against cisplatin, and matrix 
metalloproteinase (MMP)-2 expression, which was stimulated 
by exogenous ET-1, and inhibited by BQ123 and the 
phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. 
In line with this, knockdown of EDNRA had the opposite 
effect. EDNRA over-expression stimulated colon cancer liver 
metastases in a mouse model, and its knockdown produced 
the opposite effect (67).
 EDN-1 is over-expressed in cytoplasm, stroma and blood 
vessels of human colon cancer, whereas in normal mucosa 
cells, EDN-1 expression is limited to apical layers of the 
epithelium, vascular endothelial cells and surrounding stroma. 
The plasma level of EDN-1 was found over-expressed in 
colorectal cancer patients, both with primary tumor and with 
metastases, and in a rat model of colorectal cancer. Moreover, 
intraportal injection of the selective EDNRA antagonist BQ123 
reduced the weight of colorectal metastatic lesions inside the 
liver (33).
 In a phase 1 clinical trial, the EDNRA antagonist atrasentan 
was used in 31 patients with prostate, colorectal, breast, lung, 
and renal cell carcinoma. There was some pains relieve and 
reduction in some tumor markers, but no radiological response 
or significant clinical benefit was detected (68).
 Although the receptors EDNRA and EDNRB are similarly 
distributed in arteries supplying colorectal cancer and normal 
colon in the same colorectal cancer patients, the EDNRB 
antagonist BQ788 reduced the contractile response produced 
by EDN1 in arteries supplying colorectal tumor, but not that 
of arteries supplying normal colon, meanwhile, the EDNRA 
antagonist BQ123 reduced both types of arteries equally. It was 
deduced that arteries of colorectal cancer are more susceptible 
to EDN-1 due to EDNRB enhanced activity (69). 
 In colorectal cancer tissues from 42 human patient samples, 
there was hyper-methylation of the EDNRB promoter and 
this epigenetic silencing was associated with lower levels of 
EDNRB mRNA. This may indicate that EDNRB is a tumor 
suppressor gene, which is down-regulated by promoter 
hyper-methylation (70). There is growing interest in using 
endothelin receptor antagonists as adjuvant therapy, after 
failure of monotherapy. For example, there is an ongoing phase 
II clinical trial in patients with metastatic colorectal cancer 
with ZD4054 in combination with irinotecan, fluorouracil and 
folinicacid (FOLFIRI) after failure of oxaliplatin containing 
chemotherapy (71).
ENDOTHELIN SYSTEM AND NON-CANCEROUS DISEASES
The EDN system is linked with many pathological conditions 
such as cardiac and vascu lar diseases (congestive cardiac 
failure, coronary artery diseases, essential hypertension, 
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atherosclerosis, Raynauds disease, and preeclampsia), renal 
diseases (acute renal injury, chronic renal failure, and renal 
remodeling), central nervous system disease (cerebrovascular 
disease), pulmonary diseases (asthma, cryptogenic fibrosing 
alveolitis, and pulmonary hypertension), and developmental 
disease (Hirschsprung’s disease) (2).
 Animals with knockout of ECE1, or deficient in the 
EDN-1/EDNRA and EDN-3/EDNRB pathways have similar 
phenotype, they are deficient in epidermal melanocytes, and 
therefore have white-spotted hair and skin color, but a normal 
eye color. Also, their distal colon (from sigmoid colon to 
the rectum) is narrowed and obstructed due to the absence 
of myenteric ganglia, with dilatation of the proximal colon, 
intestinal dysfunction, and premature death (72). EDNRB 
knockout mice show an aganglionic megacolon, a pigmentary 
disorder of the skin and can survive only up to 8 weeks. This 
may be due to failure of precursors of the enteric nervous 
system and neural crest-derived epidermal melanoblasts to 
colonize the intestines and skin. At the same time, EDN-3 
knockout mice have an identical phenotype (14). 
CONCLUSION
Taken together, there is a marked alteration in the expression of 
EDN system compo nents in colorectal cancer and an obvious 
role of endothelin system members in all stages of colorectal 
cancer pathogenesis. There are promising results when using 
antagonists of the endothelin system in cancer treatment, both, 
in vivo and vitro. However, clinical trials in can cer patients 
based on a monotherapy with EDN receptor antagonists are not 
encouraging, and there is a growing trend to use these drugs as 
adjuvant therapeutics in combination with other conventional 
anticancer drugs. The roles of EDN-2 and EDN-3 in cancer 
will need more research.
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